Skip to main content Skip to section navigation Skip to footer
Immunovant, Inc.
  • Home
  • About Us
    • Our Leadership
  • Our Science
    • Introduction to FcRn
    • Pipeline & Therapeutic Areas
  • Patients & Caregivers
    • Our Commitment
    • Therapeutic Areas & Clinical Trials
  • For Investors
    • Overview
    • News & Events
    • Company Info
    • Financials
    • Stock Data
    • SEC Filings
    • Governance
  • Join Us
    • Values & Culture
    • Explore Careers
  • Contact Us

IR Calendar

View Main Content
For Investors

For Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Leadership Team
    • Contacts
    • FAQ
  • Financials
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts

Immunovant Announces Plans to Study CIDP and Graves’ Disease

September 7, 2022 8:00 am EST
CIDP Key Opinion Leader Discussion (Full)
HTML
Webcast
Audio
Presentation
PDF
  • Email Alerts
  • Contacts
  • RSS News Feed
©2024 Immunovant, Inc. All rights reserved.
Privacy Policy Terms of Use Disclaimer Sitemap Manage Cookie Preferences